24.26
price down icon0.86%   -0.21
after-market 시간 외 거래: 24.36 0.10 +0.41%
loading
전일 마감가:
$24.47
열려 있는:
$24.59
하루 거래량:
33.39M
Relative Volume:
0.79
시가총액:
$137.93B
수익:
$62.46B
순이익/손실:
$7.88B
주가수익비율:
17.58
EPS:
1.38
순현금흐름:
$11.22B
1주 성능:
-4.30%
1개월 성능:
+1.21%
6개월 성능:
-8.93%
1년 성능:
-19.05%
1일 변동 폭
Value
$24.25
$24.65
1주일 범위
Value
$24.25
$25.44
52주 변동 폭
Value
$20.91
$31.54

화이자 Stock (PFE) Company Profile

Name
명칭
Pfizer Inc
Name
전화
(212) 733-2323
Name
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Name
직원
81,000
Name
트위터
@Pfizer
Name
다음 수익 날짜
2025-02-04
Name
최신 SEC 제출 서류
Name
PFE's Discussions on Twitter

PFE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
PFE
Pfizer Inc
24.26 144.12B 62.46B 7.88B 11.22B 1.38
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.18 717.60B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
164.36 377.32B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
184.85 338.30B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
114.14 234.32B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.92 306.33B 43.59B 15.04B 10.74B 3.3766

화이자 Stock (PFE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-22 개시 Cantor Fitzgerald Neutral
2024-12-10 재개 BofA Securities Neutral
2024-11-15 개시 Wolfe Research Underperform
2024-10-25 재개 Citigroup Neutral
2024-10-17 개시 Bernstein Mkt Perform
2024-08-07 업그레이드 Daiwa Securities Neutral → Outperform
2024-03-22 다운그레이드 Argus Buy → Hold
2024-02-23 개시 Guggenheim Buy
2024-01-04 다운그레이드 TD Cowen Outperform → Market Perform
2023-10-20 재개 UBS Neutral
2023-10-16 업그레이드 Jefferies Hold → Buy
2023-07-17 재확인 JP Morgan Neutral
2023-07-14 개시 HSBC Securities Buy
2023-06-29 다운그레이드 Credit Suisse Outperform → Neutral
2023-05-11 다운그레이드 Daiwa Securities Outperform → Neutral
2023-03-06 개시 Jefferies Hold
2023-02-07 업그레이드 Daiwa Securities Neutral → Outperform
2023-01-26 다운그레이드 UBS Buy → Neutral
2023-01-17 다운그레이드 Wells Fargo Overweight → Equal Weight
2023-01-04 다운그레이드 BofA Securities Buy → Neutral
2022-12-13 업그레이드 Goldman Neutral → Buy
2022-11-18 개시 Credit Suisse Outperform
2022-05-23 개시 SVB Leerink Mkt Perform
2022-04-06 재개 Morgan Stanley Equal-Weight
2022-01-05 업그레이드 BofA Securities Neutral → Buy
2022-01-03 재확인 Bernstein Mkt Perform
2021-12-20 재확인 Cowen Outperform
2021-12-17 개시 Goldman Neutral
2021-12-13 업그레이드 UBS Neutral → Buy
2021-12-09 개시 Wells Fargo Overweight
2021-11-19 개시 BMO Capital Markets Outperform
2021-07-27 재개 Truist Buy
2021-05-06 다운그레이드 Mizuho Buy → Neutral
2021-04-07 재개 RBC Capital Mkts Sector Perform
2021-02-04 업그레이드 DZ Bank Hold → Buy
2020-12-16 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2020-11-19 재개 Goldman Neutral
2020-11-10 재개 Bernstein Mkt Perform
2020-10-12 다운그레이드 Atlantic Equities Overweight → Neutral
2020-09-29 개시 Berenberg Hold
2020-06-16 개시 SVB Leerink Mkt Perform
2020-02-27 개시 Barclays Equal Weight
2020-02-27 업그레이드 Standpoint Research Hold → Buy
2020-02-06 개시 Mizuho Buy
2020-01-07 개시 RBC Capital Mkts Outperform
2019-10-17 재개 BofA/Merrill Neutral
2019-07-30 다운그레이드 BofA/Merrill Buy → Neutral
2019-07-30 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2019-06-04 재개 Morgan Stanley Overweight
2019-02-20 재개 Citigroup Neutral
2019-01-31 업그레이드 Argus Hold → Buy
2019-01-31 업그레이드 Credit Suisse Neutral → Outperform
2019-01-23 다운그레이드 UBS Buy → Neutral
2018-12-11 다운그레이드 JP Morgan Overweight → Neutral
2018-11-01 다운그레이드 BMO Capital Markets Outperform → Market Perform
모두보기

화이자 주식(PFE)의 최신 뉴스

pulisher
10:01 AM

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail

10:01 AM
pulisher
08:15 AM

2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade - The Motley Fool

08:15 AM
pulisher
Jul 20, 2025

Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? - AOL.com

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Pfizer Inc. stock priceFree Stock Market Return Analysis - Jammu Links News

Jul 20, 2025
pulisher
Jul 20, 2025

Pfizer Inc. Stock Analysis and ForecastOutstanding stock performance - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Can Pfizer Limited (PFIZER) Maintain Its ValuationFree Market Volatility Navigation Tips - Jammu Links News

Jul 19, 2025
pulisher
Jul 19, 2025

Is Pfizer Inc. a good long term investmentOutstanding trading profits - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

What analysts say about Pfizer Inc. stockTremendous portfolio expansion - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Pfizer’s Discounted Stock Offers Yield, But Risks Linger - Finimize

Jul 19, 2025
pulisher
Jul 19, 2025

Sally Susman helped steer Pfizer through COVID-19. Her advice for leaders? Learn to write — and listen. - Business Insider

Jul 19, 2025
pulisher
Jul 18, 2025

Pfizer’s (PFE) Dividend Safety: Balancing Innovation and Shareholder Returns - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Morgan Stanley Maintains a Hold on Pfizer (PFE) - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s Hemophilia Study: Insights into Treatment Patterns and Outcomes - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s BeneFIX Study Update: Key Insights for Investors - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s Phase 3 RSV Vaccine Study: A Potential Game-Changer in Maternal Health - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s Lyme Disease Vaccine Study: Key Insights for Investors - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer and BioNTech’s New Shingles Vaccine Study: What Investors Need to Know - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s Rimegepant Study: A New Hope for Migraine Sufferers - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s Rimegepant Study: A New Hope for Migraine Prevention? - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s ABRYSVO Vaccine Study: A Potential Game-Changer in Infant RSV Prevention - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer's Global Health Fellows Program: Leveraging Colleagues’ Expertise to Help Improve Healthcare Access Around the World - Pfizer

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer’s Latest Study on PF-07799544: A Potential Game-Changer for Advanced Solid Tumors - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Rx Rundown: Sarep­ta Ther­a­peu­tics, Juul, Pfizer and more - Medical Marketing and Media

Jul 18, 2025
pulisher
Jul 18, 2025

BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum

Jul 18, 2025
pulisher
Jul 18, 2025

13 Cheap Stocks Under $50 to Buy Now - Insider Monkey

Jul 18, 2025
pulisher
Jul 17, 2025

Pfizer, Lilly spend big on telehealth contracts: Lawmaker report - Sherwood News

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters

Jul 17, 2025
pulisher
Jul 17, 2025

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit - insights.citeline.com

Jul 17, 2025
pulisher
Jul 17, 2025

Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer Just Reversed Its Bull Run. Is It A Buy Or A Sell? - Investor's Business Daily

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off - Benzinga

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer (PFE) Expands Patient Access With Eliquis (Apixaban) Direct Purchase Program - simplywall.st

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer’s EPIC-Peds Study: A Potential Game-Changer for Pediatric COVID-19 Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer’s Phase 1 Study on PF-07941944: Key Insights for Investors - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer’s Pediatric Leukemia Study: Implications for BESPONSA’s Market Potential - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to offer Eliquis at a discount for some patients - BioPharma Dive

Jul 17, 2025
pulisher
Jul 17, 2025

Major drugmakers offer big discount on blood thinner Eliquis - Fox Business

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol-Myers Squibb (BMY) and Pfizer (PFE) Stocks Jump on Eliquis Drug Discount - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters

Jul 17, 2025
pulisher
Jul 17, 2025

Pfizer Inc.'s (NYSE:PFE) recent 3.7% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance

Jul 17, 2025
pulisher
Jul 17, 2025

Lifestyle Drugs Market Future Business Opportunities - openPR.com

Jul 17, 2025
pulisher
Jul 17, 2025

How Bristol Myers Squibb and Pfizer's Direct-to-Patient Eliquis Initiative is Reshaping Anticoagulant Access and Profitability - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount - Bloomberg

Jul 17, 2025
pulisher
Jul 17, 2025

BMS-Pfizer alliance to offer Eliquis at 40% discount to cash-paying patients - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer Slash Eliquis Price by 40% with New Direct-to-Patient Program for Top Blood Thinner - Stock Titan

Jul 17, 2025
pulisher
Jul 17, 2025

Exclusive | Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount - The Wall Street Journal

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer To Offer Blood Thinning Drug At Discount: Retail Chatter Around BMY Jump 60% In 24 Hours - Stocktwits

Jul 17, 2025
pulisher
Jul 16, 2025

Pfizer’s Latest Clinical Study: A New Hope for Advanced Melanoma Treatment? - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

Pfizer’s INLYTA® Study Completion: Real-World Insights and Market Impact - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

Pfizer’s Hemophilia Study Completion: Market Implications and Insights - TipRanks

Jul 16, 2025

화이자 (PFE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$108.28
price up icon 0.06%
drug_manufacturers_general SNY
$47.93
price down icon 0.81%
$295.87
price up icon 0.38%
drug_manufacturers_general MRK
$79.31
price down icon 0.81%
drug_manufacturers_general NVO
$64.92
price up icon 0.95%
자본화:     |  볼륨(24시간):